Bio-Path (NASDAQ:BPTH) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Bio-Path (NASDAQ:BPTH) in a research note released on Wednesday morning. The brokerage issued a sell rating on the stock.

Bio-Path Stock Down 5.9 %

BPTH opened at $0.16 on Wednesday. Bio-Path has a 12-month low of $0.12 and a 12-month high of $7.67. The business has a 50 day moving average of $0.45 and a 200-day moving average of $0.77.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.